Regulation Tracker
Peptide legal status in 2026
Prescribed peptides from a licensed 503A pharmacy are legal. Compounded is not the same as FDA-approved. And seven compounds are one committee vote away from a status change.
The one-paragraph answer
Prescribed peptides, dispensed by a licensed 503A compounding pharmacy against a patient-specific
prescription, are legal. Compounded medications are not FDA-approved as finished products —
that's a different statement from illegal. What's actively in flux is which peptides
compounding pharmacies may use, which is exactly what the July 2026 PCAC meeting decides.Status by compound
| Compound | Status | Notes |
|---|---|---|
| Semaglutide | LEGAL NOW | FDA-approved brand; compounded versions legal but shortage resolved Feb 2025, narrowing compounding authority |
| Tirzepatide | LEGAL NOW | FDA-approved brand; shortage resolved Dec 2024 |
| BPC-157 | PENDING REVIEW | Under PCAC review July 2026; staff briefing proposes not adding to 503A bulks list |
| TB-500 | PENDING REVIEW | Under PCAC review July 2026 |
| KPV | PENDING REVIEW | Under PCAC review July 2026 |
| MOTS-C | PENDING REVIEW | Under PCAC review July 2026 |
| DSIP (Emideltide) | PENDING REVIEW | Under PCAC review July 2026 |
| Semax | PENDING REVIEW | Under PCAC review July 2026 |
| Epitalon | PENDING REVIEW | Under PCAC review July 2026 |
| Retatrutide | RESTRICTED | Investigational — cannot be compounded at all. No legal prescribed route exists. |
The two things that determine legality
- Is there a patient-specific prescription? 503A compounding requires a clinician to document a patient-specific need. Mass-marketed compounded product without that is what the FDA has been sending warning letters about.
- Is the bulk substance permitted? A compounding pharmacy can only use bulk drug substances on (or eligible for) the FDA's 503A bulks list. That list is what PCAC advises on.
"Research use only" is not a legal shield
Vendors selling peptides labeled "not for human consumption" while marketing them for human use have been
a specific FDA warning-letter target. The disclaimer is not legal protection for the seller — and it
provides you no protection at all. Research vs prescribed →This page updates
We re-verify this tracker monthly and after every material FDA action. Next scheduled update: after the
July 23–24 PCAC votes. See what's under review →FAQ
Are peptides legal in the US?
Prescribed peptides dispensed by a licensed 503A compounding pharmacy against a patient-specific prescription are legal. They are not FDA-approved as finished products, which is a different thing. Research-grade peptides sold 'for research use only' occupy a gray zone that FDA enforcement has been actively narrowing.
Is BPC-157 banned?
Not currently. But an FDA staff briefing ahead of the July 2026 PCAC meeting proposes BPC-157 not be added to the 503A approved bulks list. If that recommendation is adopted, compounding pharmacies face tighter restrictions on preparing it — which restricts prescribed access without being an outright ban.
Why can't I get retatrutide prescribed anywhere?
Retatrutide is an investigational drug that has not completed clinical trials. It cannot legally be compounded under any circumstances. There is no legal prescribed route to it in 2026, regardless of what any vendor claims.
Medical disclaimer: Veritide is an independent consumer-research publication, not a healthcare provider or pharmacy. This page is informational and is not medical advice. Compounded medications are not FDA-approved as finished products. Always consult a licensed clinician before starting any peptide or GLP-1 therapy.